Resampling phase III data to assess phase II Trial designs and endpoints

Clinical Cancer Research

Volumn 18, Issue 8, 2012, Pages 2309-2315

  Sharma, Manish R ^a   Karrison, Theodore G ^a   Jin, Yuyan ^b   Bies, Robert R ^c   Maitland, Michael L ^a   Stadler, Walter M ^a   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b PFIZER INC   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AE 941; PLACEBO; SORAFENIB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFECT; DRUG EFFICACY; EVALUATION RESEARCH; EVIDENCE BASED MEDICINE; HUMAN; INTERMETHOD COMPARISON; KIDNEY CANCER; MAJOR CLINICAL STUDY; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REFERENCE DATABASE; SIMULATION; STUDY DESIGN; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TUMOR VOLUME;

BENZENESULFONATES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84859828707     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1815     Document Type: Article

References (25)

1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
2. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10. (Pubitemid 19099520)
3. Sharma MR, Stadler WM, Ratain MJ. Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst 2011;103:1093-100.
4. Tang H, Foster NR, Grothey A, Ansell SM, Goldberg RM, Sargent DJ. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J Clin Oncol 2010;28:1936-41.
5. Gan HK, Grothey A, Pond GR, Moore MJ, Siu LL, Sargent D. Randomized phase II trials: inevitable or inadvisable? J Clin Oncol 2010;28:2641-7.
6. Cannistra SA. Phase II trials in journal of clinical oncology. J Clin Oncol 2009;27:3073-6.
7. Michaelis LC, Ratain MJ. Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties. Clin Cancer Res 2007;13:2400-5. (Pubitemid 46698590)
8. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 2007;25:209-16. (Pubitemid 350003036)
9. Maitland ML, Hudoba C, Snider KL, Ratain MJ. Analysis of the yield of phase II combination therapy trials in medical oncology. Clin Cancer Res 2010;16:5296-302.
10. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 2004;22:4442-5. (Pubitemid 41185107)
11. El-Maraghi RH, Eisenhauer EA. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. J Clin Oncol 2008;26:1346-54.
12. Lavin PT. An alternative model for the evaluation of antitumor activity. Cancer Clin Trials 1981;4:451-7.
13. Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 2007;99:1455-61.
14. Wang Y, Sung C, Dartois C, Ramchandani R, Booth BP, Rock E, et al. Elucidation of relationship between tumor size and survival in non-small- cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther 2009;86:167-74.
15. Claret L, Girard P, Hoff PM, Van Cutsem E, Zuideveld KP, Jorga K, et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 2009;27:4103-8.
16. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34. (Pubitemid 46089673)
17. Escudier B, Choueiri TK, Oudard S, Szczylik C, Négrier S, Ravaud A, et al. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol 2007;178:1901-5. (Pubitemid 47538612)
18. Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, et al. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res 2010;16:1764-918.
19. Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, Oudard S, et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol 2011;60:644-61.
20. Wieand S, Therneau T. A two-stage design for randomized trials with binary outcomes. Control Clin Trials 1987;8:20-8. (Pubitemid 17040575)
21. Ratain MJ, Karrison TG. Testing the wrong hypothesis in phase II oncology trials: there is a better alternative. Clin Cancer Res 2007;13:781-2. (Pubitemid 46340347)
22. Batist G, Patenaude F, Champagne P, Croteau D, LevintonC, Hariton C, et al. Neovastat (AE-941) in refractory renalcellcarcinomapatients: report of a phase II trial with two dose levels. Ann Oncol 2002;13:1259-63. (Pubitemid 34960135)
23. Rubinstein LV, Dancey JE, Korn EL, Smith MA, Wright JJ. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise? J Natl Cancer Inst 2007;99:1422-3.
24. Fridlyand J, Kaiser LD, Fyfe G. Analysis of tumor burden versus progression-free survival for phase II decision making. Contemp Clin Trials 2011;32:446-52.
25. An MW, Mandrekar SJ, Branda ME, Hillman SL, Adjei AA, Pitot HC, et al. Comparison of continuous versus categorical tumor measurement- based metrics to predict overall survival in cancer treatment trials. Clin Cancer Res 2011;17:6592-9.